CL2018000497A1 - Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa - Google Patents
Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopaInfo
- Publication number
- CL2018000497A1 CL2018000497A1 CL2018000497A CL2018000497A CL2018000497A1 CL 2018000497 A1 CL2018000497 A1 CL 2018000497A1 CL 2018000497 A CL2018000497 A CL 2018000497A CL 2018000497 A CL2018000497 A CL 2018000497A CL 2018000497 A1 CL2018000497 A1 CL 2018000497A1
- Authority
- CL
- Chile
- Prior art keywords
- levodopa
- oxime derivative
- therapy
- induced dyskinesia
- chromone oxime
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004502 levodopa Drugs 0.000 title abstract 3
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical class C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title abstract 3
- 208000012661 Dyskinesia Diseases 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000000149 penetrating effect Effects 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención proporciona un derivado de oxima de cromona de la fórmula (I), que es un modulador de los receptores del sistema nervioso sensibles al glutamato de aminoácido neuroexcitatorio y presenta una exposición cerebral convenientemente alta con la administración oral, para el tratamiento o prevención de disquinesia inducida por levodopa. La presente invención también proporciona una terapia mejorada de la enfermedad de Parkinson, utilizando el derivado de oxima de cromona de la fórmula (I) en combinación con levodopa.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| EP15188368 | 2015-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000497A1 true CL2018000497A1 (es) | 2018-06-01 |
Family
ID=54260666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000497A CL2018000497A1 (es) | 2015-08-27 | 2018-02-23 | Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10532057B2 (es) |
| EP (2) | EP3341380B1 (es) |
| JP (1) | JP2018528205A (es) |
| KR (1) | KR20180041234A (es) |
| CN (1) | CN108349993A (es) |
| AU (1) | AU2016313138A1 (es) |
| CA (1) | CA2995313A1 (es) |
| CL (1) | CL2018000497A1 (es) |
| CY (1) | CY1122401T1 (es) |
| DK (1) | DK3341380T3 (es) |
| DO (1) | DOP2018000060A (es) |
| EA (1) | EA035016B1 (es) |
| ES (1) | ES2764490T3 (es) |
| HR (1) | HRP20192250T1 (es) |
| HU (1) | HUE047531T2 (es) |
| IL (1) | IL257655A (es) |
| LT (1) | LT3341380T (es) |
| MA (1) | MA42700B1 (es) |
| ME (1) | ME03591B (es) |
| MX (1) | MX2018002255A (es) |
| NI (1) | NI201800031A (es) |
| PH (1) | PH12018500430A1 (es) |
| PL (1) | PL3341380T3 (es) |
| PT (1) | PT3341380T (es) |
| RS (1) | RS59651B1 (es) |
| RU (1) | RU2018110580A (es) |
| SI (1) | SI3341380T1 (es) |
| SM (1) | SMT201900720T1 (es) |
| TN (1) | TN2018000061A1 (es) |
| WO (1) | WO2017032874A1 (es) |
| ZA (1) | ZA201801642B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3186257B1 (en) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| PT3341380T (pt) | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
| KR20210039368A (ko) | 2018-07-26 | 2021-04-09 | 도메인 테라퓨틱스 | 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도 |
| EP3807077A4 (en) | 2018-12-14 | 2021-12-29 | Hewlett-Packard Development Company, L.P. | Evaluating candidate virtual build volumes |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
| KR102903389B1 (ko) * | 2022-11-30 | 2025-12-23 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| JP2010533147A (ja) | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス．エイ． | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| EP2493871B1 (en) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| EA026419B1 (ru) * | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| EP3186257B1 (en) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| PT3341380T (pt) | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
-
2016
- 2016-08-26 PT PT167698729T patent/PT3341380T/pt unknown
- 2016-08-26 AU AU2016313138A patent/AU2016313138A1/en not_active Abandoned
- 2016-08-26 CN CN201680062784.8A patent/CN108349993A/zh active Pending
- 2016-08-26 HU HUE16769872A patent/HUE047531T2/hu unknown
- 2016-08-26 LT LTEP16769872.9T patent/LT3341380T/lt unknown
- 2016-08-26 US US15/755,435 patent/US10532057B2/en not_active Expired - Fee Related
- 2016-08-26 WO PCT/EP2016/070175 patent/WO2017032874A1/en not_active Ceased
- 2016-08-26 ES ES16769872T patent/ES2764490T3/es active Active
- 2016-08-26 EP EP16769872.9A patent/EP3341380B1/en active Active
- 2016-08-26 HR HRP20192250TT patent/HRP20192250T1/hr unknown
- 2016-08-26 RS RS20191571A patent/RS59651B1/sr unknown
- 2016-08-26 DK DK16769872.9T patent/DK3341380T3/da active
- 2016-08-26 EA EA201890590A patent/EA035016B1/ru not_active IP Right Cessation
- 2016-08-26 CA CA2995313A patent/CA2995313A1/en not_active Abandoned
- 2016-08-26 MA MA42700A patent/MA42700B1/fr unknown
- 2016-08-26 SI SI201630559T patent/SI3341380T1/sl unknown
- 2016-08-26 PL PL16769872T patent/PL3341380T3/pl unknown
- 2016-08-26 EP EP19207959.8A patent/EP3696182A1/en not_active Withdrawn
- 2016-08-26 KR KR1020187008542A patent/KR20180041234A/ko not_active Withdrawn
- 2016-08-26 JP JP2018510876A patent/JP2018528205A/ja active Pending
- 2016-08-26 TN TNP/2018/000061A patent/TN2018000061A1/en unknown
- 2016-08-26 SM SM20190720T patent/SMT201900720T1/it unknown
- 2016-08-26 RU RU2018110580A patent/RU2018110580A/ru not_active Application Discontinuation
- 2016-08-26 ME MEP-2019-346A patent/ME03591B/me unknown
- 2016-08-26 MX MX2018002255A patent/MX2018002255A/es unknown
-
2018
- 2018-02-21 IL IL257655A patent/IL257655A/en unknown
- 2018-02-23 CL CL2018000497A patent/CL2018000497A1/es unknown
- 2018-02-23 NI NI201800031A patent/NI201800031A/es unknown
- 2018-02-26 DO DO2018000060A patent/DOP2018000060A/es unknown
- 2018-02-27 PH PH12018500430A patent/PH12018500430A1/en unknown
- 2018-03-09 ZA ZA2018/01642A patent/ZA201801642B/en unknown
-
2019
- 2019-12-10 CY CY20191101297T patent/CY1122401T1/el unknown
- 2019-12-11 US US16/709,988 patent/US20200171042A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000497A1 (es) | Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| CL2015002641A1 (es) | Método para el tratamiento de la enfermedad de parkinson. | |
| CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
| BR112017005104A2 (pt) | derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina | |
| CL2018001395A1 (es) | Composiciones farmacéuticas que comprenden amida de levodopa y sus uso | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CL2020000383A1 (es) | Composiciones de aminoácidos para el tratamiento de lesión neuronal. | |
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| CR20120255A (es) | Derivados de purina o deazapurina útiles para el tratamiento de inter alia infecciones virales | |
| CL2018002692A1 (es) | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) | |
| PE20151771A1 (es) | Composiciones nutricionales que contienen un componente neurologico y los usos del mismo | |
| BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
| MX353165B (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| BR112016018063A2 (pt) | Dispositivo de fixação, e, método de fixação de um primeiro substrato em um segundo substrato | |
| AR105089A1 (es) | ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| CU20200012A7 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2016011837A (es) | Composiciones de inhibidores de la dopa decarboxilasa. | |
| BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| BR112019000946A2 (pt) | compostos para imagiologia dos agregados da proteína tau |